Home	Fast Track My Amedeo FAQ About	Flying Publisher
Fast Track	FPG #8: Alternative Treatments in Psychiatry FPG #7: Critical Care in Neurology	Free Medical Books

Lung Cancer

Free Subscription Articles published in Cancer Chemother Pharmacol Retrieve available abstracts of 47 articles: HTML format Text format

Single Articles

February 2012
1. YU Y , Xu X, Du Z, Shi M, et al
   Non-platinum regimens of gemcitabine plus docetaxel versus platinum-based regimens in first-line treatment of advanced non-small cell lung cancer: a meta-analysis on 9 randomized controlled trials.
   Cancer Chemother Pharmacol. 2012.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   January 2012
2. KOBAYASHI T , Koizumi T, Agatsuma T, Yasuo M, et al
   A phase II trial of erlotinib in patients with EGFR wild-type advanced non-small-cell lung cancer.
   Cancer Chemother Pharmacol. 2012.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
3. KITAGAWA C , Saka H, Kajikawa S, Mori K, et al
   Phase I and pharmacologic study of weekly amrubicin in patients with refractory or relapsed lung cancer: Central Japan Lung Study Group (CJLSG) 0601 trial.
   Cancer Chemother Pharmacol. 2012.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   December 2011
4. HIRAIKE M , Hiraki Y, Misumi N, Hanada K, et al
   Pharmacokinetics of carboplatin in a hemodialysis patient with small-cell lung cancer.
   Cancer Chemother Pharmacol. 2011.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
5. PEI KL , Yuan Y, Qin SH, Wang Y, et al
   CIP-13F, a novel aminopeptidase N (APN/CD13) inhibitor, inhibits Lewis lung carcinoma growth and metastasis in mice.
   Cancer Chemother Pharmacol. 2011.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
6. WADA M , Yamamoto M, Ryuge S, Nagashima Y, et al
   Phase II study of S-1 monotherapy in patients with previously treated, advanced non-small-cell lung cancer.
   Cancer Chemother Pharmacol. 2011.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
7. JAKOBSEN JN , Sorensen JB
   Intratumor heterogeneity and chemotherapy-induced changes in EGFR status in non-small cell lung cancer.
   Cancer Chemother Pharmacol. 2011.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
8. KOLINSKY K , Tovar C, Zhang YE, Railkar A, et al
   Preclinical evaluation of the novel multi-targeted agent R1530.
   Cancer Chemother Pharmacol. 2011;68:1585-94.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
9. SOTO E , Staab A, Doege C, Freiwald M, et al
   Comparison of different semi-mechanistic models for chemotherapy-related neutropenia: application to BI 2536 a Plk-1 inhibitor.
   Cancer Chemother Pharmacol. 2011;68:1517-27.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   November 2011
10. MURAKAMI H , Tamura T, Takahashi T, Nokihara H, et al
    Phase I study of continuous afatinib (BIBW 2992) in patients with advanced non-small cell lung cancer after prior chemotherapy/erlotinib/gefitinib (LUX-Lung 4).
    Cancer Chemother Pharmacol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
11. WAKELEE HA , Takimoto CH, Lopez-Anaya A, Chu Q, et al
    The effect of bexarotene on atorvastatin pharmacokinetics: results from a phase I trial of bexarotene plus chemotherapy in patients with advanced non-small cell lung cancer.
    Cancer Chemother Pharmacol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
12. WAKELEE HA , Middleton G, Dunlop D, Ramlau R, et al
    A phase I pharmacokinetic study of bexarotene with vinorelbine and cisplatin in patients with advanced non-small-cell lung cancer (NSCLC).
    Cancer Chemother Pharmacol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
13. RODON J , Jacobs CD, Chu Q, Rowinsky EK, et al
    A phase I pharmacokinetic study of bexarotene with paclitaxel and carboplatin in patients with advanced non-small cell lung cancer (NSCLC).
    Cancer Chemother Pharmacol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
14. MAKINO Y , Yamamoto N, Sato H, Ando R, et al
    Pharmacokinetic and pharmacodynamic study on amrubicin and amrubicinol in Japanese patients with lung cancer.
    Cancer Chemother Pharmacol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    October 2011
15. CHOW LQ , Blais N, Jonker DJ, Laurie SA, et al
    A phase I dose-escalation and pharmacokinetic study of sunitinib in combination with pemetrexed in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer.
    Cancer Chemother Pharmacol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    September 2011
16. MIN JH , Lee HY, Lim H, Ahn MJ, et al
    Drug-induced interstitial lung disease in tyrosine kinase inhibitor therapy for non-small cell lung cancer: a review on current insight.
    Cancer Chemother Pharmacol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
17. TAKAHASHI T , Nakamura Y, Tsuya A, Murakami H, et al
    Pharmacokinetics of aprepitant and dexamethasone after administration of chemotherapeutic agents and effects of plasma substance P concentration on chemotherapy-induced nausea and vomiting in Japanese cancer patients.
    Cancer Chemother Pharmacol. 2011;68:653-9.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    July 2011
18. GROSSI F , de Marinis F, Gebbia V, Riccardi F, et al
    A randomised phase II trial of two sequential schedules of docetaxel and cisplatin followed by gemcitabine in patients with advanced non-small-cell lung cancer.
    Cancer Chemother Pharmacol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
19. CHEN L , Zheng SZ, Sun ZG, Wang AY, et al
    Cryptotanshinone has diverse effects on cell cycle events in melanoma cell lines with different metastatic capacity.
    Cancer Chemother Pharmacol. 2011;68:17-27.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    June 2011
20. HONG J , Jung M, Kim YJ, Sym SJ, et al
    Phase II study of combined belotecan and cisplatin as first-line chemotherapy in patients with extensive disease of small cell lung cancer.
    Cancer Chemother Pharmacol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
21. TOGASHI Y , Masago K, Fukudo M, Tsuchido Y, et al
    Efficacy of increased-dose erlotinib for central nervous system metastases in non-small cell lung cancer patients with epidermal growth factor receptor mutation.
    Cancer Chemother Pharmacol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
22. CHENG CY , Cherng SH, Wu WJ, Yang TY, et al
    Regulation of chemosensitivity and migration by clusterin in non-small cell lung cancer cells.
    Cancer Chemother Pharmacol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
23. MASUDA T , Hattori N, Hamada A, Iwamoto H, et al
    Erlotinib efficacy and cerebrospinal fluid concentration in patients with lung adenocarcinoma developing leptomeningeal metastases during gefitinib therapy.
    Cancer Chemother Pharmacol. 2011;67:1465-9.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
24. SHAO C , Lu C, Chen L, Koty PP, et al
    p53-Dependent anticancer effects of leptomycin B on lung adenocarcinoma.
    Cancer Chemother Pharmacol. 2011;67:1369-80.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
25. PALLIS AG , Chandrinos V, Pavlakou G, Xenidis N, et al
    A multicenter phase I trial of metronomic oral vinorelbine plus cisplatin in patients with NSCLC.
    Cancer Chemother Pharmacol. 2011;67:1239-45.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    May 2011
26. QI WX , Shen Z, Yao Y
    Meta-analysis of docetaxel-based doublet versus docetaxel alone as second-line treatment for advanced non-small-cell lung cancer.
    Cancer Chemother Pharmacol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
27. JOERGER M , Burgers JA, Baas P, Doodeman VD, et al
    Gene polymorphisms, pharmacokinetics, and hematological toxicity in advanced non-small-cell lung cancer patients receiving cisplatin/gemcitabine.
    Cancer Chemother Pharmacol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
28. KONINGS IR , Sleijfer S, Mathijssen RH, de Bruijn P, et al
    Increasing tumoral 5-fluorouracil concentrations during a 5-day continuous infusion: a microdialysis study.
    Cancer Chemother Pharmacol. 2011;67:1055-62.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    April 2011
29. SEN F , Saglam EK, Toker A, Dilege S, et al
    Weekly docetaxel and cisplatin with concomitant radiotherapy in addition to surgery and/or consolidation chemotherapy in stage III non-small cell lung cancer.
    Cancer Chemother Pharmacol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
30. METRO G , Chiari R, Mare M, Giannarelli D, et al
    Carboplatin plus pemetrexed for platinum-pretreated, advanced non-small cell lung cancer: a retrospective study with pharmacogenetic evaluation.
    Cancer Chemother Pharmacol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    March 2011
31. GU Y , Guise CP, Patel K, Abbattista MR, et al
    Reductive metabolism of the dinitrobenzamide mustard anticancer prodrug PR-104 in mice.
    Cancer Chemother Pharmacol. 2011;67:543-55.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    February 2011
32. ZHOU ZT , Zhou FX, Wei Q, Zou LY, et al
    Phase II study of cisplatin/etoposide and endostar for extensive-stage small-cell lung cancer.
    Cancer Chemother Pharmacol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
33. STATHOPOULOS GP , Antoniou D, Dimitroulis J, Stathopoulos J, et al
    Comparison of liposomal cisplatin versus cisplatin in non-squamous cell non-small-cell lung cancer.
    Cancer Chemother Pharmacol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    December 2010
34. CHOUAID C , Nathan F, Pemberton K, Morris T, et al
    A phase II, randomized, multicenter study to assess the efficacy, safety, and tolerability of zibotentan (ZD4054) in combination with pemetrexed in patients with advanced non-small cell lung cancer.
    Cancer Chemother Pharmacol. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
35. YODA S , Soejima K, Yasuda H, Naoki K, et al
    A phase I study of S-1 and irinotecan combination therapy in previously treated advanced non-small cell lung cancer patients.
    Cancer Chemother Pharmacol. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
36. TAKAKUWA O , Oguri T, Ozasa H, Uemura T, et al
    Over-expression of MDR1 in amrubicinol-resistant lung cancer cells.
    Cancer Chemother Pharmacol. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
37. YU W , Chen L, Yang YQ, Falck JR, et al
    Cytochrome P450 omega-hydroxylase promotes angiogenesis and metastasis by upregulation of VEGF and MMP-9 in non-small cell lung cancer.
    Cancer Chemother Pharmacol. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    November 2010
38. TOUIL YS , Seguin J, Scherman D, Chabot GG, et al
    Improved antiangiogenic and antitumour activity of the combination of the natural flavonoid fisetin and cyclophosphamide in Lewis lung carcinoma-bearing mice.
    Cancer Chemother Pharmacol. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
39. KOTSAKIS A , Agelaki S, Vardakis N, Stathopoulos G, et al
    A dose-escalation study of pemetrexed and docetaxel in non-small-cell lung cancer.
    Cancer Chemother Pharmacol. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
40. CHEN J , Emara N, Solomides C, Parekh H, et al
    Resistance to platinum-based chemotherapy in lung cancer cell lines.
    Cancer Chemother Pharmacol. 2010;66:1103-11.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
41. PAIK PK , Rudin CM, Brown A, Rizvi NA, et al
    A phase I study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in solid tumor malignancies.
    Cancer Chemother Pharmacol. 2010;66:1079-85.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    September 2010
42. SAHU RP , Batra S, Kandala PK, Brown TL, et al
    The role of K-Ras gene mutation in TRAIL-induced apoptosis in pancreatic and lung cancer cell lines.
    Cancer Chemother Pharmacol. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
43. XU XH , Su J, Fu XY, Xue F, et al
    Clinical effect of erlotinib as first-line treatment for Asian elderly patients with advanced non-small-cell lung cancer.
    Cancer Chemother Pharmacol. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
44. XENIDIS N , Vardakis N, Varthalitis I, Giassas S, et al
    Alpha multicenter phase II study of pegylated liposomal doxorubicin in combination with irinotecan as second-line treatment of patients with refractory small-cell lung cancer.
    Cancer Chemother Pharmacol. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
45. OGURI T , Shimokata T, Inada M, Ito I, et al
    Pharmacokinetic analysis of carboplatin in patients with cancer who are undergoing hemodialysis.
    Cancer Chemother Pharmacol. 2010;66:813-7.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    August 2010
46. TANG CH , Parham C, Shocron E, McMahon G, et al
    Picoplatin overcomes resistance to cell toxicity in small-cell lung cancer cells previously treated with cisplatin and carboplatin.
    Cancer Chemother Pharmacol. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
47. SUZUKI M , Endo M, Shinohara F, Echigo S, et al
    Rapamycin suppresses ROS-dependent apoptosis caused by selenomethionine in A549 lung carcinoma cells.
    Cancer Chemother Pharmacol. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    

Thank you for your interest in scientific medicine.

Amedeo is a Flying Publisher website.    Design: